TP53 and myelodysplastic syndrome: Eprenetapopt (APR-246, PRIMA-1MET) was developed as a mut-p53 targeted therapy and is currently under clinical investigation in TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) (2).